Company
Headquarters: Cranbury, NJ, United States
Founded: February 4, 2002
Employees: 496
CEO: Mr. John F. Crowley
$4.41 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $598.7 M |
| EBITDA | $38.6 M |
| Gross Profit TTM | $537.5 M |
| Profit Margin | -2.35% |
| Operating Margin | 20.27% |
| Quarterly Revenue Growth | 19.50% |
Amicus Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: FOLD wb_incandescent
Stock: BMV: FOLD wb_incandescent
Stock: FSX: AM6 wb_incandescent
John Crowley (Chairman and Chief Executive Officer) Bradley Campbell (President and Chief Operating Officer) Daphne Quimi (Chief Financial Officer) David Clark (Chief People Officer)